Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $261548.0.

  • PAVmed's Gains from Sales and Divestitures changed N/A to $261548.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $261548.0, marking a year-over-year change of. This contributed to the annual value of $136096.0 for FY2024, which is 5522.86% down from last year.
  • Per PAVmed's latest filing, its Gains from Sales and Divestitures stood at $261548.0 for Q3 2025.
  • In the past 5 years, PAVmed's Gains from Sales and Divestitures ranged from a high of $541666.0 in Q2 2022 and a low of $1016.0 during Q1 2025
  • Its 4-year average for Gains from Sales and Divestitures is $230031.0, with a median of $219320.0 in 2023.
  • As far as peak fluctuations go, PAVmed's Gains from Sales and Divestitures skyrocketed by 7952.99% in 2023, and later tumbled by 9622.47% in 2025.
  • Over the past 4 years, PAVmed's Gains from Sales and Divestitures (Quarter) stood at $169320.0 in 2022, then surged by 79.53% to $303980.0 in 2023, then tumbled by 55.23% to $136096.0 in 2024, then soared by 92.18% to $261548.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $261548.0 for Q3 2025, versus $2032.0 for Q2 2025 and $1016.0 for Q1 2025.